Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Summary

This study is a single arm, multi-centre phase II study of olaparib and bevacizumab combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line (systemic) therapy. Subjects will receive olaparib and bevacizumab combination therapy. The arm is composed of 28 subjects. Olaparib 300 mg bid per os every 12 hours administered each cycle day and bevacizumab 15 mg/kg via IV administered on Day 1 of every cycle for every 3 weeks. One cycle consists of 21 days.

Timeline

Start

2021-06-11

Primary completion

2023-10-27

Completion

2023-10-27

Drugs

Indications